Context Therapeutics Inc. (CNTX) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Context Therapeutics Inc.

    NASDAQ: CNTX · Real-Time Price · USD
    0.82
    -0.01 (-0.98%)
    At close: Sep 05, 2025, 3:57 PM
    0.83
    1.29%
    After-hours: Sep 05, 2025, 06:36 PM EDT

    Context Therapeutics Income Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Revenue
    		 n/a n/a n/a n/a
    Cost of Revenue
    		 n/a n/a n/a n/a
    Gross Profit
    		 n/a -12.04K -9.27K n/a
    Operating Income
    		 -29.92M -25.07M -15.38M -10.53M
    Interest Income
    		 3.2M 1.16M 547.27K 64.24
    Pretax Income
    		 -26.73M -23.96M -14.84M -10.46M
    Net Income
    		 -26.73M -23.96M -14.84M -10.46M
    Selling & General & Admin
    		 7.22M 7.29M 7.79M 3.63M
    Research & Development
    		 22.7M 17.78M 7.09M 3.81M
    Other Expenses
    		 n/a n/a -2K n/a
    Operating Expenses
    		 29.92M 25.07M 14.88M 7.44M
    Interest Expense
    		 n/a n/a 547.27K 64.24K
    Selling & Marketing Expenses
    		 n/a n/a n/a n/a
    Cost & Expenses
    		 29.92M 25.07M 14.88M 7.44M
    Income Tax Expense
    		 n/a n/a n/a n/a
    Shares Outstanding (Basic)
    		 58.42M 15.97M 15.97M 2.83M
    Shares Outstanding (Diluted)
    		 58.42M 15.97M 15.97M 2.83M
    EPS (Basic)
    		 -0.46 -1.5 -0.93 -3.69
    EPS (Diluted)
    		 -0.46 -1.5 -0.93 -3.69
    EBITDA
    		 -26.67M -25.06M -14.83M -10.53M
    EBIT
    		 -26.73M -25.07M -14.84M -7.44M
    Depreciation & Amortization
    		 52.7K 12.04K 9.27K -3.09M

    Add to Watchlist